Stryker Co. (NYSE:SYK) Shares Acquired by Klingman & Associates LLC

Klingman & Associates LLC boosted its stake in Stryker Co. (NYSE:SYK) by 321.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,700 shares of the medical technology company’s stock after acquiring an additional 2,823 shares during the quarter. Klingman & Associates LLC’s holdings in Stryker were worth $1,337,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Assetmark Inc. lifted its holdings in Stryker by 30.7% in the 3rd quarter. Assetmark Inc. now owns 1,013 shares of the medical technology company’s stock valued at $366,000 after purchasing an additional 238 shares in the last quarter. Verdence Capital Advisors LLC lifted its stake in shares of Stryker by 19.8% in the third quarter. Verdence Capital Advisors LLC now owns 1,621 shares of the medical technology company’s stock worth $586,000 after buying an additional 268 shares in the last quarter. Washington Trust Advisors Inc. boosted its position in Stryker by 47.7% during the third quarter. Washington Trust Advisors Inc. now owns 443 shares of the medical technology company’s stock worth $160,000 after acquiring an additional 143 shares during the last quarter. CWA Asset Management Group LLC purchased a new stake in Stryker during the 3rd quarter valued at about $1,345,000. Finally, Leavell Investment Management Inc. grew its stake in Stryker by 24.4% during the 3rd quarter. Leavell Investment Management Inc. now owns 1,111 shares of the medical technology company’s stock valued at $402,000 after acquiring an additional 218 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.7 %

Shares of NYSE SYK opened at $375.96 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $361.46 and a 200 day moving average price of $345.63. Stryker Co. has a 52 week low of $266.93 and a 52 week high of $377.83. The stock has a market capitalization of $143.32 billion, a price-to-earnings ratio of 40.30, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $2.46 EPS. Equities research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analysts Set New Price Targets

SYK has been the subject of several analyst reports. Barclays increased their price target on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Morgan Stanley increased their price objective on Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Needham & Company LLC raised their target price on shares of Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $393.65.

Insider Activity

In related news, insider Viju Menon sold 600 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Viju Menon sold 600 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock worth $24,825,275 over the last 90 days. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.